Prion-like propagation of alpha-synuclein aggregates in the brain of wild-type mice
|
|
- Roberta Magdalene Montgomery
- 5 years ago
- Views:
Transcription
1 Prion-like propagation of alpha-synuclein aggregates in the brain of wild-type mice Nolwen L. Rey, PhD Patrik Brundin s Laboratory, Van Andel Research Institute Grand Rapids, Michigan, USA 15th Annual Mild Cognitive Impairment (MCI) Symposium 14 january 2017 No conflict of interest to disclose
2 - Synuclein and Parkinson s disease Mandel et al Lewy bodies (LB) and Lewy neurites, hallmarks of Parkinson s disease -Synuclein Misfolded and hyper phosphorylated α-syn Death of midbrain dopamine neurons is key to motor symptoms Braak et al Cell and Tissue Research Dauer and Prezedborski, 2003, Neuron Non-motor symptoms are also a major issue
3 Fetal neuron transplants in Parkinson s disease Lund Fetal DA neurons Grafting Multiple donors for each brain
4 Young transplanted neurons with Lewy bodies TH in Substantia Nigra: α-synuclein in Striatal graft: in Striatal graft: Lewy bodies in grafted neurons in at least 9 cases from 5 different surgical centers Li et al. 2008, Nat Med, 2010, Mov Dis
5 Cell-to-cell transfer: Prion-like propagation hypothesis Donor cell Recipient cell 1- Release 2- Uptake 3- Seeding Adapted from Angot et al. 2010
6 First animal model of cell-to-cell transfer Graft Fetal mesencephalic tissue AAV hu α-syn Angot et al PloS One Modified from Kirik et al. 2004, Nat Neurosc
7 -Synuclein seeding in vivo, and propagation Brain lysate Synthetic PFFs Mougenot et al Neurobiology of Aging Adapted from Polymenidou and Cleveland, 2012 JEM Luk et al J Exp Med Propagation along connections (as suggested in humans)?
8 Parkinson s disease staging Hawkes et al , 2009, 2010 Braak et al. 2002, 2003, 2004 Neocortex (secondary & primary) Neocortex association Mesocortex Substantia nigra, Amygdala Locus coeruleus Dorsal IX / X nucleus, Olfactory bulb Hyposmia Constipation Bladder disorder Sleep disorder Depression Presymptomatic Phase Unilateral tremor Rigidity Akinesia Poor balance Time (years) Symptomatic Phase Falls Cognitive decline Dementia Dependency Stage 2 routes of progression?
9 Olfactory system in Parkinson s disease α-syn pathology: first in the olfactory bulb (then in the DMX) (Beach et al. 2009, Braak and Del Tredici 2016) Olfactory dysfunction: > 4 years before clinical diagnosis of PD Beach et al. 2009, Acta Neuropathologica Prevalence: 75-96% in patients with PD (Attems et al Acta Neuropathologica) The olfactory system is involved in prodromal Parkinson s disease
10 Olfactory bulb pathology model Cell-to-cell transfer and propagation of α-syn during prodromal PD are potential therapeutic targets Create a model of progressive α-syn pathology of direct relevance to prodromal PD Rey et al, JEM 2016
11 Olfactory bulb pathology model α-syn fibrils (PFFs) 250um [α-syn monomer and PBS as controls] Injection into the olfactory bulb Wild type mice 1 month 3 months 6 months 12 months Olfactory tests α-syn neuropathology Rey et al, JEM 2016
12 Pser129 -syn pathology in olfactory structures Rey et al, JEM 2016
13 Pser129 pathology -syn propagation Rey et al, JEM 2016
14 Inclusions positive for markers of Lewy bodies in neurons Rey et al, JEM 2016
15 Odorant dilution Progressive olfactory deficits Rey et al, JEM 2016 Odorant detection threshold >10-2 >10-2 >10-2 Controls PBS mms mpffs Severe deficit of odor detection in PFFs-injected mice mo 3mo 6mo 12mo Time after injection Severe deficit of odor retention in PFFs-injected mice
16 Concluding remarks Neuron-to-neuron transfer in vivo Seeding in vivo Propagation of pathology between distal brain regions, following neuronal connections Mechanisms of initiation of pathology? Mechanisms of transmission between cells/ distal brain regions? Non-neuronal cells involved in propagation?
17 Brundin Lab- Grand Rapids Patrik Brundin Sonia George Emily Schulz Jennifer Steiner Darcy Marckini Former Brundin Lab- Lund, Sweden Elodie Angot Alicja Flasch Ulrika Nordström Marie Persson-Vejgården Acknowledgements V Lee s lab, UPenn Philadelphia Kelvin C Luk Virginia M-Y Lee John Trojanowski R Melki s lab, CNRS France Ronald Melki Luc Bousset J Ma s Lab -VAI Jiyan Ma Xinhe Wang Katelyn Becker Vivarium VAI Elissa Boguslawski Stephen Bowman Bryn Eagleson Tristan Kempston Statistical core VAI Zach Madaj Mary Winn Research Funding Van Andel Research Institute Peter C. & Emajean Cook Foundation Multipark (Lund) ERC (Lund) Contact me at: Nolwen.Rey@vai.org
The Parkinson s You Can t See
The Parkinson s You Can t See We principally see the motor phenomena of Parkinson's disease, but is there an early stage without visible features? Might this provide a window for disease-modifying therapy?
More informationNew Approach to Parkinson s Disease: Synuclein Immunotherapy
RB2014 Conference August 22, 2014 New Approach to Parkinson s Disease: Synuclein Immunotherapy Dale Schenk, PhD President and CEO Prothena Corporation plc Primary Motor and Non-Motor Symptoms of Parkinson
More informationFOUNDATION OF UNDERSTANDING PARKINSON S DISEASE
FOUNDATION OF UNDERSTANDING PARKINSON S DISEASE DEE SILVER M.D MOVEMENT DISORDER SPECIALIST MEDICAL DIRECTOR -- PARKINSON ASSOCIATION OF SAN DIEGO 1980 TO PRESENT SCRIPPS MEMORIAL HOSPITAL, LA JOLLA CA.
More informationThe Latest Research in Parkinson s Disease. Lawrence Elmer, MD, PhD Professor, Dept. of Neurology University of Toledo
The Latest Research in Parkinson s Disease Lawrence Elmer, MD, PhD Professor, Dept. of Neurology University of Toledo OR.. Rethinking Parkinson s Disease Lawrence Elmer, MD, PhD Professor, Dept. of Neurology
More informationHow to Diagnose Early (Prodromal) Lewy Body Dementia. Ian McKeith MD, FRCPsych, F Med Sci.
How to Diagnose Early (Prodromal) Lewy Body Dementia Ian McKeith MD, FRCPsych, F Med Sci. Parkinson s Disease Lewy Body Disease Time PD Dementia Lewy Body Dementias Dementia with Lewy Bodies (DLB) Diagnostic
More information2/5/2015. Sensitive: Discriminative: Simple Inexpensive. Example of a good biomarker: blood tests, CSF test but they are not discriminative for PD
Jeffrey H. Kordower, Ph.D.. Department of Neurological Sciences Rush University Medical Center Sensitive: Discriminative: Simple Inexpensive Example of a good biomarker: blood tests, CSF test but they
More informationModeling Parkinson s disease: systems to test gene-environment interactions
Modeling Parkinson s disease: systems to test gene-environment interactions Jason Cannon, Ph.D. Pittsburgh Institute of Neurodegenerative Diseases University of Pittsburgh Outline Parkinson s disease (PD)
More informationIII./3.1. Movement disorders with akinetic rigid symptoms
III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.
More informationPresented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn
Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Objectives What agents do we currently have available and what do we ideally need? What biomarkers exist for
More information2/14/2013. The Pathogenesis of Parkinson s Disease. February, inherited forms of PD. Autosomal Recessive Parkinson s Disease
inherited forms of PD The Pathogenesis of Parkinson s Disease February, 2013 PARK1 dominant α-synuclein presynaptic protein PARK2 recessive parkin E3 ubiquitin ligase PARK3 dominant 2p13? PARK4 dominant
More informationMaking Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease
Making Every Little Bit Count: Parkinson s Disease SHP Neurobiology of Development and Disease Parkinson s Disease Initially described symptomatically by Dr. James Parkinson in 1817 in An Essay on the
More informationEvaluation of Parkinson s Patients and Primary Care Providers
Evaluation of Parkinson s Patients and Primary Care Providers 2018 Movement Disorders Half Day Symposium Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 6/28/2018 1 Disclosures GE Speaker,
More informationEarly Clinical Features of Parkinson s Disease and Related Disorders. Dr. Alastair Noyce
1 Specialist Registrar in Neurology, London Deanery Parkinson s UK Doctoral Research Fellow Project lead for PREDICT-PD Declarations Salary: Parkinson's UK, Barts and the London NHS Trust Grants: Parkinson's
More informationCheyenne 11/28 Neurological Disorders II. Transmissible Spongiform Encephalopathy
Cheyenne 11/28 Neurological Disorders II Transmissible Spongiform Encephalopathy -E.g Bovine4 Spongiform Encephalopathy (BSE= mad cow disease), Creutzfeldt-Jakob disease, scrapie (animal only) -Sporadic:
More informationKurt A. Jellinger. 2 nd Int. Conference BrainNet Europe, Munich, Dec , 2008 NAC A30P A53T ALPHA HELICAL HYDROPHOBIC ACID (GLU-PRO) COOH
2 nd Int. Conference BrainNet Europe, Munich, Dec. 10-12, 2008 NH 3 1 NAC 125 133 136 A30P A53T 125 140 ALPHA HELICAL HYDROPHOBIC ACID (GLU-PRO) COOH 29 71 82 125 129 (Src) (GRK5, CK-1 & CK-2) Kurt A.
More informationNeuropathology of Neurodegenerative Disorders Prof. Jillian Kril
Neurodegenerative disorders to be discussed Alzheimer s disease Lewy body diseases Frontotemporal dementia and other tauopathies Huntington s disease Motor Neuron Disease 2 Neuropathology of neurodegeneration
More informationThe Marmoset Monkey as Model for Neurological Disorders
The Marmoset Monkey as Model for Neurological Disorders Jan Langermans and Ingrid Philippens From Laboratory to Clinic Disease models neuroscience: Parkinson, Sleep, Stress, Alzheimer, MS MS Models: rhmog
More informationNeurodegenerative Disease. April 12, Cunningham. Department of Neurosciences
Neurodegenerative Disease April 12, 2017 Cunningham Department of Neurosciences NEURODEGENERATIVE DISEASE Any of a group of hereditary and sporadic conditions characterized by progressive dysfunction,
More informationInvestigating molecular mechanisms of progression of Parkinson s Disease in human brain
Investigating molecular mechanisms of progression of Parkinson s Disease in human brain Murray ; C.E., Pressey ; S.N., Heywood 2 ; W.E., Hargreaves 3 ; I.P., Neergheen 3 ; V., Wauters ; S., Palkovits 4
More informationREDEFINING PARKINSON S DISEASE
REDEFINING PARKINSON S DISEASE Did James Parkinson Get It Right? Matthew B. Stern, M.D. University of Pennsylvania USA 1 Hoxton Square W. Poewe, Austria J. Obeso, Spain E. Tolosa, Spain M. Stern, USA To
More information05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century
Peter Silburn Professor Clinical Neuroscience University of Queensland Queensland Brain Institute Neurosciences Queensland Impact of in Australia Second most common neurodegenerative disorder Up to 64,000
More informationLearnings from Parkinson s disease: Critical role of Biomarkers in successful drug development
Learnings from Parkinson s disease: Critical role of Biomarkers in successful drug development Ken Marek Coalition Against Major Diseases and FDA 2014 Annual Scientific Workshop Oct 2014 Disclosure Co-founder
More informationMalattia di Parkinson: patogenesi molecolare e nuove strategie terapeutiche
LA NEUROSONOLOGIA NELLE PATOLOGIE DEGENERATIVE E VASCOLARI CEREBRALI San Benedetto del Tronto 6-8 novembre 2017 Malattia di Parkinson: patogenesi molecolare e nuove strategie terapeutiche Giuseppe De Michele
More informationFDG-PET e parkinsonismi
Parkinsonismi FDG-PET e parkinsonismi Valentina Berti Dipartimento di Scienze Biomediche, Sperimentali e Cliniche Sez. Medicina Nucleare Università degli Studi di Firenze History 140 PubMed: FDG AND parkinsonism
More informationNIH Public Access Author Manuscript Parkinsonism Relat Disord. Author manuscript; available in PMC 2009 January 1.
NIH Public Access Author Manuscript Published in final edited form as: Parkinsonism Relat Disord. 2008 ; 14(Suppl 2): S84 S87. doi:10.1016/j.parkreldis.2008.04.004. Strengths and Limitations of Genetic
More informationKelly Mills, MD, MHS Johns Hopkins Parkinson s Disease and Movement Disorders Center
Kelly Mills, MD, MHS Johns Hopkins Parkinson s Disease and Movement Disorders Center Disclosures Research support from St. Jude / Abbott Funding National Institutes of Health / NINDS Parkinson Foundation
More informationThe Biology of Parkinson s Disease and its treatments
The Biology of Parkinson s Disease and its treatments Paola Sacchetti, Ph.D. Assistant Professor Director MS Neuroscience Department of Biology University of Hartford, CT psacchett@hartford.edu (860)768-5926
More informationStaging of Sporadic Parkinson Disease-Related a-synuclein Pathology: Inter- and Intra-Rater Reliability
J Neuropathol Exp Neurol Copyright Ó 2005 by the American Association of Neuropathologists, Inc. Vol. 64, No. 7 July 2005 pp. 623 628 ORIGINAL ARTICLE Staging of Sporadic Parkinson Disease-Related a-synuclein
More informationPart I: 2017 UPDATE ON OUR CURRENT UNDERSTANDING OF PARKINSON DISEASE
Part I: 2017 UPDATE ON OUR CURRENT UNDERSTANDING OF PARKINSON DISEASE Hubert H. Fernandez, MD, FAAN Cleveland Clinic Cleveland, OH In the last decade, advancements in pathology, genetics, biomarkers, and
More informationPathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)
Pathogenesis of Degenerative Diseases and Dementias D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Dementias Defined: as the development of memory impairment and other cognitive deficits
More informationUNDERSTANDING PARKINSON S DISEASE
UNDERSTANDING PARKINSON S DISEASE WHAT IS PARKINSON S DISEASE? A progressive disease of the nervous system marked by tremor, muscular rigidity, and slow, imprecise movement, chiefly affecting middleaged
More informationUPDATE ON RESEARCH IN PARKINSON S DISEASE
UPDATE ON RESEARCH IN PARKINSON S DISEASE Charles H. Adler, M.D., Ph.D. Professor of Neurology Mayo Clinic College of Medicine Co-Principal Investigator Arizona Parkinson s Disease Consortium Arizona Study
More informationPROGESTERONE AND THE STRIATAL 6-HYDROXYDOPAMINE MODEL OF PARKINSON S DISEASE. A thesis submitted
PROGESTERONE AND THE STRIATAL 6-HYDROXYDOPAMINE MODEL OF PARKINSON S DISEASE A thesis submitted in partial fulfilment of the requirements for the Degree of Doctor of Philosophy in Psychology At the University
More informationParkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817.
Parkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817. Four (4) hallmark clinical signs: 1) Tremor: (Note -
More informationNeurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients
Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients Alex Iranzo 1,2 *, Ana Fernández-Arcos 1, Eduard Tolosa 1,2,Mónica Serradell 1, José Luis Molinuevo 1, Francesc
More informationLa neurosonologia. Ecografia cerebrale e nuove applicazioni nelle malattie neurodegenerative. Nelle patologie degenerative e vascolari cerebrali
La neurosonologia Nelle patologie degenerative e vascolari cerebrali Andrea Pilotto Ecografia cerebrale e nuove applicazioni nelle malattie neurodegenerative Prof. Daniela Berg Department of Neurodegeneration
More informationParkinson s UK Brain Bank
Parkinson s UK Brain Bank From Brain to Breakthrough Dr George Gveric Manager 19 October 2018 Coordinated approach Donors Relatives Information Reporting Researchers Tissue supply Quality assurance Expertise
More informationParkinson e decadimento cognitivo. Stelvio Sestini
Parkinson e decadimento cognitivo Stelvio Sestini Patients with PD can develop a spectrum of cognitive symptoms Heterogeneity of cognitive deficits The cognitive symptoms can evolve to dementia (Mov Disorder
More informationTreatment of Parkinson s Disease: Present and Future
Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing
More informationDementia and Healthy Ageing : is the pathology any different?
Dementia and Healthy Ageing : is the pathology any different? Professor David Mann, Professor of Neuropathology, University of Manchester, Hope Hospital, Salford DEMENTIA Loss of connectivity within association
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Treatment Advances Tuesday, January 26, 2016 Welcome and Introductions Stephanie Paul Vice President Development and Marketing American Parkinson Disease Association 1
More informationStrategies for Neurorestoration: Growth Factors
Strategies for Neurorestoration: Growth Factors Elena Posse de Chaves, PhD 928-MSB Phone: 492-5966 Email: elena.chaves@ualberta.ca Treatment of Neurodegenerative Diseases Most neurodegenerative diseases
More informationSupplementary Materials for. c-abl Activation Plays a Role in α-synucleinopathy Induced Neurodegeneration
Supplementary Materials for c-abl Activation Plays a Role in α-synucleinopathy Induced Neurodegeneration Saurav Brahmachari, Preston Ge, Su Hyun Lee, Donghoon Kim, Senthilkumar S. Karuppagounder, Manoj
More informationParkinson disease (PD) and dementia with Lewy bodies. Involvement of the Cerebellum in Parkinson Disease and Dementia with Lewy Bodies
BRIEF COMMUNICATION Involvement of the Cerebellum in Parkinson Disease and Dementia with Lewy Bodies Kay Seidel, PhD, 1 Mohamed Bouzrou, 1 Nina Heidemann, 1 Rejko Kr uger, MD, 2 Ludger Sch ols, MD, 3 Wilfred
More informationNovel Targets of disease modifying therapy for Parkinson disease. David G. Standaert, MD, PhD John N. Whitaker Professor and Chair of Neurology
Novel Targets of disease modifying therapy for Parkinson disease David G. Standaert, MD, PhD John N. Whitaker Professor and Chair of Neurology Disclosures Dr. Standaert has served as a paid consultant
More informationSynaptic changes in dementia: links to cognition and behaviour
Synaptic changes in dementia: links to cognition and behaviour Paul T Francis, PhD Professor of Neurochemistry Director, Brains for Dementia Research Agenda Discuss synaptic changes in various dementias
More informationCell transplantation in Parkinson s disease
Cell transplantation in Parkinson s disease Findings by SBU Alert Published September 18, 2001 Revised November 7, 2003 Version 2 Technology and target group: In Parkinsons disease, the brain cells that
More informationImpairment of Neurogensis in the Olfactory Bulb of Transgenic Mice Overexpressing Human Wildtype Alpha Synuclein Under the Thy-1 Promoter
Impairment of Neurogensis in the Olfactory Bulb of Transgenic Mice Overexpressing Human Wildtype Alpha Synuclein Under the Thy-1 Promoter Parkinson s disease (PD) is a progressive neurodegenerative disorder
More informationBiomedical Technology Research Center 2011 Workshop San Francisco, CA
Diffusion Tensor Imaging: Parkinson s Disease and Atypical Parkinsonism David E. Vaillancourt court1@uic.edu Associate Professor at UIC Departments t of Kinesiology i and Nutrition, Bioengineering, and
More informationCOGNITIVE IMPAIRMENT IN PARKINSON S DISEASE
1 GENERAL INTRODUCTION GENERAL INTRODUCTION PARKINSON S DISEASE Parkinson s disease (PD) is a neurodegenerative movement disorder, named after James Parkinson who described some of its characteristic
More informationMannitol - A natural food supplement shown to arrest Parkinson's progression and reverse symptoms
Mannitol - A natural food supplement shown to arrest Parkinson's progression and reverse symptoms A www.fight-parkinsons.org report This could be a game-changer for many people You just never know what
More information25 th Annual Southern California Alzheimer s Disease Research Conference
25 th Annual Southern California Alzheimer s Disease Research Conference New Guidelines and Importance of Brain Donation Thomas J. Montine, MD, PhD Alvord Professor & Chair Department of Pathology University
More informationOverview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits
Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:
More informationDEMENTIA IN PARKINSON`S DISEASE. DR C PADMAKUMAR MD FRACP FRCP(Edin) Director-Parkinson`s Disease Service for the Older Person HNELHD
DEMENTIA IN PARKINSON`S DISEASE DR C PADMAKUMAR MD FRACP FRCP(Edin) Director-Parkinson`s Disease Service for the Older Person HNELHD DEMENTIA IN PD The concept of Non Motor Symptoms in PD Dementia in Parkinson`s
More informationTreatment of Neurological Disorders. David Stamler, MD Chief Medical Officer and SVP, Clinical Development January, 2018
Treatment of Neurological Disorders David Stamler, MD Chief Medical Officer and SVP, Clinical Development January, 2018 1 Corporate Overview Developing first-in-class therapies to treat orphan and non-orphan
More informationMOVEMENT DISORDERS AND DEMENTIA
MOVEMENT DISORDERS AND DEMENTIA FOCUS ON DEMENTIA WITH LEWY BODIES MADHAVI THOMAS MD NORTH TEXAS MOVEMENT DISORDERS INSTITUTE, INC DEMENTIA de men tia dəˈmen(t)sh(ē)ə/ nounmedicine noun: dementia a chronic
More informationRecent Advances in the cause and treatment of Parkinson disease. Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL
Recent Advances in the cause and treatment of Parkinson disease Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL SOME BACKGROUND incidence rate (per 100.000 person years)
More informationTargeting the Gut-Brain axis in Parkinson s disease
Targeting the Gut-Brain axis in Parkinson s disease Paula Pérez Pardo The work of this thesis was financially supported by Nutricia Research and is part of the Utrecht University Focus en Massa program.
More informationDISORDERS OF THE MOTOR SYSTEM. Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine
DISORDERS OF THE MOTOR SYSTEM Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine THE MOTOR SYSTEM To understand disorders of the motor system, we need to review how a
More informationExtrapyramidal Motor System. Basal Ganglia or Striatum. Basal Ganglia or Striatum 3/3/2010
Extrapyramidal Motor System Basal Ganglia or Striatum Descending extrapyramidal paths receive input from other parts of motor system: From the cerebellum From the basal ganglia or corpus striatum Caudate
More informationImaging biomarkers for Parkinson s disease
3 rd Congress of the European Academy of Neurology Amsterdam, The Netherlands, June 24 27, 2017 Teaching Course 6 MDS-ES/EAN: Neuroimaging in movement disorders - Level 2 Imaging biomarkers for Parkinson
More informationNeuroprotection in preclinical models of Parkinson disease by the NAPVSIPQ peptide
Neuroprotection in preclinical models of Parkinson disease by the NAPVSIPQ peptide Bruce H. Morimoto, Ph.D. Executive Director, Applied Translational Medicine Microtubules Microtubules essential for neuronal
More informationDistinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation
Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation Article Published Version Creative Commons: Attribution 4.0 (CC BY) Open Access
More informationMetabolomic Profiling of Bile Acids in an Experimental Model of Prodromal Parkinson s Disease
H OH OH metabolites Article Metabolomic Profiling of Bile Acids in an Experimental Model of Prodromal Parkinson s Disease Stewart F. Graham 1,2, *, Nolwen L. Rey 3, Zafer Ugur 1, Ali Yilmaz 1, Eric Sherman
More informationProdromal and Early Parkinson s Disease Diagnosis
Prodromal and Early Parkinson s Disease Diagnosis Earlier diagnosis may lead to earlier and more effective treatments. By Sneha Mantri, MD, MS and James F. Morley, MD, PhD Since its initial description
More informationNon-motor symptoms as a marker of. Michael Samuel
Non-motor symptoms as a marker of progression in Parkinson s s disease Michael Samuel London, UK 1 Definitions and their problems Non-motor symptoms as a marker of progression Non-motor symptoms (NMS)
More informationMultiple choice questions: ANSWERS
Multiple choice questions: ANSWERS Chapter 1. Redefining Parkinson s disease 1. Common non-motor features that precede the motor findings in Parkinson s disease (PD) include all of the following except?
More informationThalamus: VA VM, MD S N. GPi Superior colliculus. compacta reticulata
. Putamen & Caudate Putamen & Caudate GPe Neocortex Thalamus: VA VM, MD S N GPi Superior colliculus compacta reticulata Substantia Nigra Pedunculopontine nuc. of midbrain ret.form. Satellites of the corpus
More informationsymptoms of Parkinson s disease EXCEPT.
M. Angele Theard, M.D Asst. Professor, Washington University, St. Louis, MO Quiz team; Shobana Rajan, M.D; Suneeta Gollapudy, MD; Verghese Cherian, M.D, M. Angele Theard, MD This quiz is being published
More informationPSYCHOSIS IN PARKINSON'S DISEASE
PSYCHOSIS IN PARKINSON'S DISEASE Objectives Identify neurobiological substrates associated with Parkinson s disease psychosis Describe the differences between older antipsychotics and novel therapies for
More informationANIMAL MODELS OF PARKINSON S DISEASE: STATE OF THE FIELD & THE FUTURE! KULDIP DAVE
ANIMAL MODELS OF PARKINSON S DISEASE: STATE OF THE FIELD & THE FUTURE! KULDIP DAVE 21 February 217 MJFF IS THE WORLD S LARGEST NONPROFIT FUNDER OF PD RESEARCH Our Mission To accelerate the development
More informationTUESDAY, MARCH 28, 2017 WEDNESDAY, MARCH 29, 2017 WELCOME RECEPTION (VIENNA CITY HALL)
KEY: PRE CONFERENCE SYMPOSIUM SPONSORED SYMPOSIUM SYMPOSIUM PLENARY LECTURE FORUM OTHER EVENT *PRE-REGISTRATION IS REQUIRED FOR THE INFORMAL NETWORKING WITH PROFESSOR LUNCH SESSION TUESDAY, MARCH 28, 2017
More informationTranscranial sonography in movement disorders
Transcranial sonography in movement disorders Uwe Walter 1st Residential Training of the European Society of Neurosonology and Cerebral Hemodynamics September 7-12, 2008 Bertinoro, Italy Department of
More informationPPMI Genetics Cohorts
PPMI Genetics Cohorts Ken Marek PPMI Genetics Kickoff Sept 16, 2013 New York, NY PPMI Genetic Cohort/Registry Symptomatic Neuron Function Prodromal P-PPMI Gen P-PPMI PPMI Diagnosis PPMI- Gen 2 PPMI-Genetics
More informationEvaluations & CE. With Support From. Featured Speaker 1/20/2016. Conflict of Interest & Disclosure Statements
With Support From University at Albany School of Public Health New York State Department of Health New York State Association of County Health Officials (NYSACHO) Parkinson s Disease: The Importance of
More informationParkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle
Parkinson s Disease in the Elderly A Physicians perspective Dr John Coyle Overview Introduction Epidemiology and aetiology Pathogenesis Diagnosis and clinical features Treatment Psychological issues/ non
More informationUSING PRECISION MEDICINE TO HELP PATIENTS WITH PARKINSON S DISEASE. The Michael J. Fox Foundation for Parkinson s Research
USING PRECISION MEDICINE TO HELP PATIENTS WITH PARKINSON S DISEASE The Michael J. Fox Foundation for Parkinson s Research MJFF IS THE WORLD S LARGEST NONPROFIT FUNDER OF PD RESEARCH Our Mission We are
More informationORIGINAL CONTRIBUTION
ORIGINAL CONTRIBUTION Evaluation of Potential Infectivity of Alzheimer and Parkinson Disease Proteins in Recipients of Cadaver-Derived Human Growth Hormone David J. Irwin, MD; Joseph Y. Abrams, MPH; Lawrence
More informationClinicopathologic and genetic aspects of hippocampal sclerosis. Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA
Clinicopathologic and genetic aspects of hippocampal sclerosis Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA The hippocampus in health & disease A major structure of the medial temporal
More informationParkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder
Prevalence Parkinson s Disease Mark S. Baron, M.D. Associate Professor of Neurology Movement Disorders Section VCU School of Medicine Common disorder Approaching 1% by 65 yrs of age, 2% by 80 yrs of age
More informationClinical Disease Progression in Parkinson s Disease Guido Alves
Clinical Disease Progression in Parkinson s Disease Guido Alves The degree philosophiae doctor (PhD) University of Bergen, Norway 06.10.2006 1 ISBN 82-308-0218-1 Bergen, Norway 2006 2 Clinical Disease
More informationThe Role of DOPAL in Parkinson s Disease. Karenee Demery. Copyright May, 2015, Karenee Demery and Koni Stone
The Role of DOPAL in Parkinson s Disease Karenee Demery Copyright May, 2015, Karenee Demery and Koni Stone Parkinson s disease is an incurable, neurodegenerative disease. The cause is still not fully understood.
More informationDISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT
Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Addressing Motor and Non-Motor Symptoms The Changing Landscape Wednesday, March 8, 2017 Welcome and Introductions Stephanie Paul Vice President Development and Marketing
More informationRasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease.
Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease. Petit, Géraldine; Berkovich, Elijahu; Hickery, Mark; Kallunki, Pekka; Fog, Karina; Fitzer-Attas, Cheryl;
More informationRole of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases
Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases Keith A. Josephs, MD, MST, MSc Professor of Neurology 13th Annual Mild Cognitive Impairment (MCI) Symposium: Alzheimer and Non-Alzheimer
More informationLecture 42: Final Review. Martin Wessendorf, Ph.D.
Lecture 42: Final Review Martin Wessendorf, Ph.D. Lecture 33 cortex Heilbronner 5 lobes of the cortex Lateral view (left side) Mid-saggital view (right side) Cellular organization of cortex White matter
More informationDifferential diagnosis of Parkinson s Disease (PD), Dementia with Lewy Bodies (DLB) & to other neuropathies with Parkinson-like syndromes
Differential diagnosis of Parkinson s Disease (PD), Dementia with Lewy Bodies (DLB) & to other neuropathies with Parkinson-like syndromes Dr. Carlos Güntner on behalf of PD. Dr. Schneider cguntner@sciencebridge.de
More informationImproving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
More informationThe motor regulator. 1) Basal ganglia/nucleus
The motor regulator 1) Basal ganglia/nucleus Neural structures involved in the control of movement Basal Ganglia - Components of the basal ganglia - Function of the basal ganglia - Connection and circuits
More informationRole of synuclein proteins in auditory function
Washington University School of Medicine Digital Commons@Becker Independent Studies and Capstones Program in Audiology and Communication Sciences 2007 Role of synuclein proteins in auditory function Catherine
More informationNutritional Considerations in Patients with Parkinson s Disease
Nutritional Considerations in Patients with Parkinson s Disease Steven Rudner, BS Nutrition & Dietetics Dietetic Intern, Sodexo Allentown www.dieteticintern.com www.sodexo.com Overview of PD Chronic progressive
More informationA. General features of the basal ganglia, one of our 3 major motor control centers:
Reading: Waxman pp. 141-146 are not very helpful! Computer Resources: HyperBrain, Chapter 12 Dental Neuroanatomy Suzanne S. Stensaas, Ph.D. March 1, 2012 THE BASAL GANGLIA Objectives: 1. What are the main
More informationNon-motor subtypes of Early Parkinson Disease in the Parkinson s Progression Markers Initiative
Non-motor subtypes of Early Parkinson Disease in the Parkinson s Progression Markers Initiative Samay Jain, MD MSc Seo Young Park, PhD University of Pittsburgh Department of Neurology and Center for Research
More informationA Parkinson s Disease and related disorders
A 3.5.2 Parkinson s Disease and related disorders 10 November 2016 Marinela Vavla marinela.vavla@kcl.ac.uk Learning objectives Basal ganglia: components and localization (inter)connections and functions
More informationUpdate on functional brain imaging in Movement Disorders
Update on functional brain imaging in Movement Disorders Mario Masellis, MSc, MD, FRCPC, PhD Assistant Professor & Clinician-Scientist Sunnybrook Health Sciences Centre University of Toronto 53 rd CNSF
More informationA. General features of the basal ganglia, one of our 3 major motor control centers:
Reading: Waxman pp. 141-146 are not very helpful! Computer Resources: HyperBrain, Chapter 12 Dental Neuroanatomy Suzanne S. Stensaas, Ph.D. April 22, 2010 THE BASAL GANGLIA Objectives: 1. What are the
More informationRedefinition of Parkinson s Disease
Redefinition of Parkinson s Disease Authors Eva Schäffer 1, Daniela Berg 1, 2 Affiliations 1 Department of Neurology, Christians-Albrechts-University of Kiel, Kiel, Germany 2 Department of Neurodegeneration,
More informationOverview of neurological changes in Alzheimer s disease. Eric Karran
Overview of neurological changes in Alzheimer s disease Eric Karran Alzheimer s disease Alois Alzheimer 1864-1915 Auguste D. 1850-1906 Case presented November 26 th 1906 Guildford Talk.ppt 20 th March,
More information(non-edited manuscript)
ONLINE FIRST This is a provisional PDF only. Copyedited and fully formatted versión will be made available at final publication Submit your article to this Journal (http://www.hh.um.es/instructions.htm)
More information